Zimmer Biomet Q2 Beat, but the Real Test Is the 2027 Sales Fix

Zimmer Biomet delivered a beat, but the market wants follow-through

Zimmer Biomet reported second-quarter net sales of $2.177 billion and adjusted diluted earnings per share were $2.07, consistent with the prior year. Management then raised full-year expectations to organic constant currency revenue guidance of 2.25%-3.25% and adjusted EPS guidance of $8.47-$8.59.

That is the core setup. The quarter was clearly better than expected, yet the beat came without year-over-year earnings growth. That helps explain the reaction in shares: investors rewarded the improved outlook, but not enough to push the stock back to its prior high.

The quarter was solid, but the bigger question is whether that solidity reflects real case activity and real buying across Zimmer's U.S. business. On that score, the results were encouraging rather than conclusive. The raised guidance gives bulls a reason to stay interested. It also raises the bar for the rest of the year.

U.S. growth and product adoption are the real proof points

The clearest near-term test is the U.S. market. Zimmer posted U.S. organic growth of 4.6%, while hips growth of 5.1% and U.S. hip growth of 5.9% pointed to healthy demand in at least one of its core segments. That matters because hips are usually a useful read on surgeon adoption and hospital acceptance.

The better result may be in the adjunct business. Technology, bone cement, and surgical segments grew 21.5%, including U.S. technology sales up more than 50%. That suggests new tools are gaining traction alongside implant procedures, which is the kind of breadth investors want to see if the commercial rebuild is working.

Product traction looks real, but it still needs to carry through

Management pointed to specific adoption drivers rather than vague pipeline optimism. In hips, the company highlighted the Z1 triple taper stem, Hammer surgical impactor, and OrthoGrid AI navigation. In robotics, it pointed to demand for Rosa and said it had completed first cases of the next generation Rosa Shoulder System.

Cash generation also looks healthy. Zimmer produced $447.9 million in operating cash flow and $308.3 million of free cash flow in the quarter. That does not prove every long-term risk is gone, but it does show the business is still funding innovation and commercial changes from within.

The 2027 sales fix is still the harder part

There is still a cleanup job. The Paragon 28 acquisition is performing exceptionally well, with sales growing mid-teens and contributing 110 basis points to full-year reported sales growth, but the broader U.S. sales-force overhaul is still scheduled to run through the end of 2027. That can improve coverage over time, but in the near term it can also create friction.

So the watch list is straightforward: - U.S. organic growth holds up after the quarter's 4.6% gain. - Hips momentum remains supported by new product adoption. - The commercial transition keeps showing fewer disruptions than feared. - Cash flow continues to support the business while investments remain in flight.

If those signs continue, the beat starts to look durable. If not, this was more of an early positive signal than a fully confirmed turnaround.

ZBH valuation: the market is paying for improvement, not perfection

After the report, ZBH traded at $99.25 in premarket trading and remained below its 52-week high of $108.29. That reads like a market paying for improvement without fully pricing in a finished recovery. In simple terms, investors liked the beat and the raised outlook, but they did not hand over extra valuation for a quarter in which adjusted diluted earnings per share were $2.07, consistent with the prior year.

What could lift the stock

The clearest bullish path is continuation of what already showed up in the quarter. If U.S. demand stays firm and the company keeps turning new-product traction into broader adoption, the raised full-year outlook becomes easier to believe. In that scenario, the gap to the prior high looks more like positioning room than a failed move.

What could weigh on the stock

The bear case is simpler. If spending needed to rebuild the U.S. commercial machine runs ahead of earnings power, investors may lose patience. Skeptics will also keep watching weaker segments and any sign that the acquisition-driven growth is not enough to offset a slower underlying pace.

What to watch next

• Whether U.S. organic growth remains strong in the next quarter.
• Whether adjusted EPS finally starts growing instead of merely holding steady.
• Whether the company's full-year ranges stay firm or need revising.
• Whether new products and the commercial overhaul keep showing tangible adoption rather than just promise.

My view: ZBH looks interesting for investors who want visible product demand and a credible operating plan. But after a quarter built on stronger sales and a still-flat earnings base, this looks more like a promising setup than an automatic buy.